|
- IRMS - Nicolae Testemitanu SUMPh
- REVISTE MEDICALE NEINSTITUȚIONALE
- Buletin de Perinatologie
- Buletin de Perinatologie 2020
- Buletin de Perinatologie Nr. 2(87) 2020
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/17079
Title: | Perspectiva pentru noi biomarkeri în afectarea renală acută și cronică |
Other Titles: | Outlook for new biomarkers in acute and chronic renal disease |
Authors: | Cazan, Corina Revenco, Ninel Hadjiu, Svetlana |
Keywords: | new biomarkers;prediction;renal disease |
Issue Date: | 2020 |
Publisher: | Instituţia Medico-Sanitară Publică Institutul Mamei și Copilului |
Citation: | CAZAN, Corina, REVENCO, Ninel, HADJIU, Svetlana. Perspectiva pentru noi biomarkeri în afectarea renală acută și cronică. In: Buletin de perinatologie. 2020, nr. 2(87), pp. 43-46. ISSN 1810-5289. |
Abstract: | The biological marker is defined as a measurable indicator of physiological and pathological biological processes
useful in assessing the stage of the disease and the pharmacological response to therapy. The paper proposes a review
of biomarkers recently involved in the early diagnosis of acute renal impairment, prognostic prediction in chronic
kidney disease, glomerular nephropathy and nephrotoxicity. Clinical trials targeting biomarkers with application in
monitoring the development, staging levels of severity for major adverse renal events, assess the response to therapeutic
intervention, risk prediction and prognosis. In the last decade, considerable progress has been made in the discovery,
development and validation of new biomarkers. Advances in biotechnology are essential for the success of clinical
trials and their application in current clinical practice. A number of urinary or serum proteins, molecules and more
recently microRNAs have been rigorously investigated as possible markers in acute kidney disease, chronic kidney
disease, forms of glomerulonephritis and autosomal dominant polycystic kidney disease. The validation of the new
biomarkers implies a long process and the implementation requires a standardized methodology, optimal cost-benefit
ratio, certain efficiency for diagnosis, therapy and prognosis. Medical practice guidelines propose the combined
use of new biomarkers for the improvement of clinical diagnosis, management and prognosis in renal impairment.
The proposed model is the one that includes the classic predictive indicators in association with new biological or
genetic markers as the only way for high quality therapeutic intervention and prognosis improvement. Biomarkers
such as IL-18, NGAL, LFABP, KIM-1 can help to characterize glomerular or tubular function, interstitial injury, or
inflammation. The measurement of biomarkers is possible in specialized centers with laboratories equipped to the
highest technological standards and the cost-benefit aspect should not be an impediment. |
metadata.dc.relation.ispartof: | Buletin de perinatologie |
URI: | https://www.mama-copilul.md/images/buletin-perinatologic/BP_2020/BP%202%20(2020).pdf http://repository.usmf.md/handle/20.500.12710/17079 |
ISSN: | 1810-5289 |
Appears in Collections: | Buletin de Perinatologie Nr. 2(87) 2020
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|